ScholarIQanswers from OpenAlex
Centre Hospitalier Universitaire de Grenoble
InstitutionResearch output, impact & collaborations
Centre Hospitalier Universitaire de Grenoble is a institution indexed in ScholarIQ from OpenAlex.
What is known about Centre Hospitalier Universitaire de Grenoble?
ScholarIQrecord summary
Centre Hospitalier Universitaire de Grenoble is a research organisation in Grenoble, FR. OpenAlex records 26,309 works and 1,650,018 citations for it. 6,216 researchers list it as their most recent affiliation.
How many works does Centre Hospitalier Universitaire de Grenoble have?
ScholarIQindexed works
Centre Hospitalier Universitaire de Grenoble has 26,309 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Centre Hospitalier Universitaire de Grenoble have?
ScholarIQcitation count
Centre Hospitalier Universitaire de Grenoble has 1,650,018 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Centre Hospitalier Universitaire de Grenoble?
ScholarIQresearcher count
Centre Hospitalier Universitaire de Grenoble has 6,216 researchers in the ScholarIQ index.
What is the average h-index at Centre Hospitalier Universitaire de Grenoble?
ScholarIQavg h-index
Centre Hospitalier Universitaire de Grenoble has an average h-index of 71.8 in OpenAlex.
What is the ROR of Centre Hospitalier Universitaire de Grenoble?
ScholarIQror
The ROR for Centre Hospitalier Universitaire de Grenoble is on the source record.
What is the OpenAlex record for Centre Hospitalier Universitaire de Grenoble?
ScholarIQopenalex
The OpenAlex for Centre Hospitalier Universitaire de Grenoble is on the source record.
What is the Wikidata of Centre Hospitalier Universitaire de Grenoble?
ScholarIQwikidata
The Wikidata for Centre Hospitalier Universitaire de Grenoble is on the source record.
Who are the most-cited researchers behind Centre Hospitalier Universitaire de Grenoble?
ScholarIQtop researchers by citations
What are the most-cited papers on Centre Hospitalier Universitaire de Grenoble?
ScholarIQmost cited works
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Олександр Войтко, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay Conev, J. Armstrong, Natalie Byrne, Norah J. Shire, Haiyi Jiang, Jonathan W. Goldman, Emilio Batagelj, Ignacio Casarini, Anea Viviana Pastor, S. Sena, Juan José Zarbá, Otto C. Burghuber, Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari, Yi‐Long Wu, Luis Paz‐Ares, Juergen Wolf, Sarayut Lucien Geater, С. В. Орлов, Diego Cortinovis, Chong‐Jen Yu, Maximillian Hochmair, Alexis B. Cortot, Chun‐Ming Tsai, Denis Moro‐Sibilot, Rosario García Campelo, Tracey McCulloch, Paramita Sen, Margaret Dugan, Serafino Pantano, Fabrice Branle, Cristian Massacesi, Gilberto de Castro
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gérard Zalcman, Julien Mazières, J. Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Olivier Molinier, R. Corre, I. Monnet, V. Gounant, F. Rivière, Henri Janicot, Radj Gervais, Chrystèle Locher, B. Milleron, Quan Le Tran, Marie-Paule Lebitasy, Franck Morin, Christian Créveuil, Jean‐Jacques Parienti, Arnaud Scherpereel
How much of the research on Centre Hospitalier Universitaire de Grenoble is open access?
ScholarIQopen access share
42%OPEN ACCESS